文献速递系统性红斑狼疮

异体脐带间充质干细胞治疗狼疮肾炎的随机双盲安慰剂对照试验

A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis.
PubMed 文献 · Ann Rheum Dis · 2017-05-06

该随机双盲安慰剂对照试验纳入18例WHO III或IV型狼疮肾炎患者,评估人脐带来源间充质干细胞(hUC-MSC)联合标准免疫抑制治疗的疗效。结果显示hUC-MSC组与安慰剂组缓解率相似,hUC-MSC未在标准免疫抑制之上显示明显额外效果,试验因无阳性治疗效应而提前终止。

要点

  • hUC-MSC组缓解9/12例(75%),安慰剂组5/6例(83%),两组缓解率相似。
  • 血清白蛋白、补体、肾功能、SLEDAI和BILAG评分改善在两组间相似。
  • hUC-MSC未在标准免疫抑制治疗之上显示明显额外疗效。

核心结论

  • hUC-MSC在标准免疫抑制治疗之上对狼疮肾炎无明显的额外治疗效应。

研究设计与样本

  • 随机双盲安慰剂对照试验纳入18例WHO III或IV型狼疮肾炎患者,随机分配至hUC-MSC(剂量2×10^8细胞)或安慰剂组。
  • 所有患者均接受标准免疫抑制治疗:静脉甲泼尼龙和环磷酰胺,随后口服泼尼松和霉酚酸酯维持。

主要发现

  • hUC-MSC组12例中9例(75%)达到缓解,安慰剂组6例中5例(83%)达到缓解。
  • 两组达到完全缓解的患者比例相似。
  • 血清白蛋白、补体、肾功能、SLEDAI和BILAG评分的改善在两组间相似。
  • 安慰剂组1例发生卒中,另1例发生腹水;hUC-MSC组1例发生白细胞减少、肺炎和皮下脓肿,另1例死于重症肺炎。

关键数值与推荐

  • 缓解定义为肾功能稳定或改善、尿红细胞和蛋白减少。

临床怎么用

  • 对于WHO III或IV型狼疮肾炎,hUC-MSC不应在标准免疫抑制治疗之外常规使用。

局限性

  • 试验在纳入18例患者后终止,因明显无法证明阳性治疗效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluate the efficacy of human umbilical cord-derived mesenchymal stem cell (hUC-MSC) for the treatment of lupus nephritis (LN). Previous reports showed hUC-MSC could have dramatic treatment effect. METHODS: Eighteen patients with WHO class III or IV LN were randomly assigned to hUC-MSC (dose 2×108 cells) or placebo. All patients received standard immunosuppressive treatment, which consisted of intravenous methylprednisolone and cyclophosphamide, followed by maintenance oral prednisolone and mycophenolate mofetil. RESULTS: Remission occurred in 9 of 12 patients (75%) in the hUC-MSC group and 5 of 6 patients (83%) in the placebo group. Remission was defined as stabilisation or improvement in renal function, reduction in urinary red cells and protein. A similar proportion of patients on hUC-MSC and placebo achieved complete remission. Improvements in serum albumin, complement, renal function, Systemic Lupus Erythematosus Disease Activity Index and British Isles Lupus Assessment Group scores were similar in both groups. One patient on placebo had a stroke and another had ascites. One patient on hUC-MSC had leucopenia, pneumonia and subcutaneous abscess and another died of severe pneumonia. The trial was abandoned after 18 patients were enrolled when it had become obvious it would not demonstrate a positive treatment effect. CONCLUSION: hUC-MSC has no apparent additional effect over and above standard immunosuppression. TRIAL REGISTRATION NUMBER: NCT01539902; Results.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Deng D, Zhang P, Guo Y, et al. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017. PMID: 28478399. doi:10.1136/annrheumdis-2017-211073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。